Background: Responses to endocrine therapies vary among patients with estrogen receptor (ERþ) breast cancer. We studied whether in utero exposure to endocrine-disrupting compounds might explain these variations. Methods: We describe a novel ERþ breast cancer model to study de novo and acquired tamoxifen (TAM) resistance. Pregnant Sprague Dawley rats were exposed to 0 or 0.1 ppm ethinyl estradiol (EE2), and the response of 9,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors to 15 mg/kg TAM, with (n ¼ 17 tumors in the controls and n ¼ 20 tumors in EE2 offspring) or without 1.2 g/kg valproic acid and 5 mg/kg hydralazine (n ¼ 24 tumors in the controls and n ¼ 32 tumors in EE2 offspring) in the female offspring, was assessed. One-sided Chi2 tests were used to calculate P values. Comparisons of differentially expressed genes between mammary tumors in in utero EE2-exposed and control rats, and between anti-estrogen-resistant LCC9 and -sensitive LCC1 human breast cancer cells, were also performed. Results: In our preclinical model, 54.2% of mammary tumors in the control rats exhibited a complete response to TAM, of which 23.1% acquired resistance with continued anti-estrogen treatment and recurred. Mammary tumors in the EE2 offspring were statistically significantly less likely to respond to TAM (P ¼ .047) and recur (P ¼ .007). In the EE2 offspring, but not in controls, adding valproic acid and hydralazine to TAM prevented recurrence (P < .001). Three downregulated and hypermethylated genes (KLF4, LGALS3, MICB) and one upregulated gene (ETV4) were identified in EE2 tumors and LCC9 breast cancer cells, and valproic acid and hydralazine normalized the altered expression of all four genes. Conclusions: Resistance to TAM may be preprogrammed by in utero exposure to high estrogen levels and mediated through reversible epigenetic alterations in genes associated with epithelial-mesenchymal transition and tumor immune responses.
[EE2]) during pregnancy increased mammary cancer risk in daughters, granddaughters, and great granddaughters in a rodent breast cancer model (5) . Increased transgenerational mammary cancer risk was accompanied by persistent changes in the DNA methylation patterns of the normal mammary glands (5) . Others reported that in utero exposure to synthetic estrogens increased expression of the polycomb gene EZH2 (6) . Thus, an elevated estrogenic environment during pregnancy induces epigenetic changes in the offspring's mammary glands that persist across several subsequent generations.
Epigenetic changes play an important role in determining the clonal landscape of primary tumors, affect how tumors respond to treatment, and define their metastatic potential (7) . They might also contribute to pre-existing differences in transcription factor expression in estrogen receptor-positive (ER þ ) breast tumors that predict the risk of recurrence (8) . How or why these patterns emerge remains largely unknown. Some may already have been present in the normal breast (9) , perhaps programmed by substantial presence of estrogenic compounds (10, 11) in the in utero environment (5) . In an earlier study, high in utero estrogenicity induced recurrence of ER þ mammary tumors in an animal model (12) . In humans, women who had high birth weight, and thus were exposed to an elevated estrogenic environment in utero (13) , are at increased risk to develop breast cancer (14) and experience an increased breast cancer mortality (15) .
In support of the importance of epigenetic changes in affecting response to cancer therapies, findings in breast cancer cells in vitro indicate that histone deacetylase (HDAC) inhibitors (MHY218, SAHA, valproic acid) and DNA methyltransferase (DNMT) inhibitor 5-aza-2'deoxycytidine (5-Aza) can reverse tamoxifen (TAM) resistance (16) (17) (18) . Munster et al. showed clinical benefit for breast cancer patients who had endocrine-resistant metastatic disease when subsequently treated with a combination of TAM and the HDAC inhibitor vorinostat (19) . Combined treatment with valproic acid and the DNMT inhibitor hydralazine is more effective in improving clinical efficacy of radiation and chemotherapy in some solid tumors, including breast cancer, than is either drug alone (20) (21) (22) .
We studied here if maternal exposure to EE2 during pregnancy affects both the response of female offspring's primary mammary tumors to TAM and tumors' subsequent recurrence patterns, and if the effects can be reversed by HDAC and DNMT inhibitors. We used valproic acid and hydralazine because these are taken chronically by humans suffering from migraines, epilepsy, or hypertension and are better tolerated than more specific HDAC and DNMT inhibitors. A modified preclinical model was used to generate ERþ mammary tumors, where rats were treated with the carcinogen 9,12-dimethylbenz[a]anthracene (DMBA). This widely validated animal model supported the preclinical development of TAM (23, 24) .
Methods

In Utero Ethinyl Estradiol (EE2) Exposure
Pregnant Sprague-Dawley dams were fed an AIN93G control diet containing either 0 or 0.1 ppm ethinyl estradiol (EE2) between gestation days 10 and 19. Subsequently, all dams and offspring were fed control diet. All animal procedures were approved by the Georgetown University Animal Care and Use Committee. Experiments were performed following the National Institutes of Health guidelines for the proper and humane use of animals in biomedical research.
Mammary Tumorigenesis and Drug Treatments
Mammary tumors were induced in the female offspring on postnatal day 50 by oral gavage of 10 mg of DMBA (Sigma). Treatments were started when rats had palpable mammary tumors 11-15 mm in diameter. The study had three treatment arms: 1) 338 ppm tamoxifen citrate (TAM, first-line treatment, administered via diet, resulting in approximately 15 mg/kg body weight daily tamoxifen dose; C: n ¼ 24 tumors; EE2: n ¼ 32 tumors); 2) 1.2g/kg daily valproic acid (Sigma) (HDAC inhibitor [25] ) and 5 mg/kg daily hydralazine (Sigma) (DNMT inhibitor [26] , administered via drinking water; C: n ¼ 59 tumors; EE2: n ¼ 48 tumors); and 3) TAM, followed by valproic acid and hydralazine as a second-line treatment using rats that had de novo TAM-resistant or partially TAM-responding tumors (control: n ¼ 17 tumors; EE2: n ¼ 20 tumors).
Response of Tumors to Adult Drug Treatments
Based on their response to TAM, tumors were divided into four categories: those exhibiting 1) complete response (CR; tumor disappeared), 2) partial response (PR; tumor stopped growing and/or started to shrink), 3) de novo resistance (tumor continued growing), and 4) acquired resistance (tumors that exhibited CR lasting more than four weeks and then recurred at the same location where they were observed initially, reaching a size of 13 mm in diameter).
RNA Target Preparation/Affymetrix Microarray Analysis
In addition to comparing differences in gene expression in adenocarcinomas between control (n ¼ 4) and EE2 (n ¼ 4) offspring prior to TAM treatment, we compared the differentially expressed genes (DEGs) between isogenic human breast cancer cell lines that either respond to anti-estrogens (LCC1/MCF-7, n ¼ 3) or exhibit anti-estrogen resistance (LCC9/MCF-7, n ¼ 3) (27) . Detailed description of these methods is provided in Supplementary Methods (available online).
Among the 48 DEGs, 27 were upregulated and 21 were downregulated in both the EE2 rat mammary tumors and LCC9 human breast cancer cells (Supplementary Table 1 , available online). We used two separate approaches to identify transcription factors that are potentially linked to anti-estrogen resistance. First, to characterize the functional roles of the DEGs, the networks hosted by these genes were constructed using differential dependency network (DDN) analysis (28, 29) . DDN identifies differential connections among transcription factors that exist only in the LCC9/in utero EE2 grouping or only in the LCC1/control grouping. Second, all DEGs were initially assessed for predicting survival in three different Gene Expression Omnibus (GEO) datasets using only tumors obtained from ERþ breast cancer patients that were subsequently treated with TAM, ie, GSE2990, GSE6532, GSE12093 (30) (31) (32) (33) (34) . We chose those transcription factors that were predictive of survival for the validation studies.
Confirmation of Changes in Gene and Protein Expression and Effect of Valproic Acid and Hydralazine
Methods are described in the Supplementary Methods and Supplementary Table 2 (available online).
Methylation Assays
Methods are described in the Supplementary Methods (available online). 
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Effect of Valproic Acid and Hydralazine on TAM Resistance in LCC9 Cells
Methods are described in the Supplementary Methods (available online).
Silencing of ETV4 in LCC9, and KLF4, LGALS3 and MICB in LCC1 Cells with siRNA
Neoadjuvant Study
Statistical Analyses
Responses of mammary tumors to TAM, with or without valproic acid and hydralazine, were analyzed using a one-sided Chi 2 test.
Two-sided two-way analysis of variance (ANOVA), followed by a two-sided Tukey test, was used to assess differences in 1) mRNA expression between LCC1 and LCC9 cells treated with vehicle, TAM, valproic acid, and hydralazine or TAM, valproic acid, and hydralazine; 2) cell proliferation in LCC1 or LCC9 cells using siRNAs to inhibit ETV4, KLF4, LGALS3, and MICB; and 3) mRNA expression between nonresponders and responders at biopsies obtained at three different time points in neo-adjuvant study. Two-sided oneway ANOVA and the Tukey test were used to determine sensitivity of LCC9 cells to TAM, valproic acid, and hydralazine vs TAM only. A two-sided Student's t test was used to determine differences in the length of TAM treatment, latency to recurrence, and CpG site methylation levels. All analyses were performed using SigmaPlot 11. A P value of less than .05 was considered statistically significant.
Results
Effect of TAM Therapy on Mammary Tumors in Control and In Utero EE2-Exposed Rats
Control rats were treated with TAM for 19.5 weeks (range ¼ 3-31 weeks). Of these rats, 54.2% exhibited a complete response (CR), factor receptor 2; IL = interleukine; ITGB4 = integrin subunit beta4; ROS = reactive oxygen species TAM ¼ tamoxifen TGFbeta = transforming growth factor beta.
8.3% a partial response (PR), and 37.5% were de novo resistant ( Figure 1A ). Twenty-three point one percent of initial CR tumors recurred ( Figure 1B ). Mean latency to recurrence was 14.7 weeks (range ¼ 8-23 weeks).
In the in utero EE2-exposed group, only 37.5% of the tumors treated with TAM exhibited CR and 53.1% were de novo resistant. Thus, the EE2 rats exhibit statistically significantly more de novo resistant mammary tumors than the controls (Chi 2 test, P ¼ .047) ( Figure 1A ). The local recurrence rate of CR tumors in the rats exposed to EE2 in utero was almost twice that seen in the controls (41.7% of CR, Chi 2 test, P ¼ .007) ( Figure 1B) . The average length of TAM treatment was significantly shorter in the EE2 group (11.8 weeks, range ¼ 2-19 weeks), but the latency to recurrence was not (10.8 weeks, range ¼ 5-17 weeks). Reflecting the higher number of de novo resistant tumors in the EE2 group, the average length of TAM treatment was statistically significantly shorter in these rats (12.8 6 1.6 weeks) than in the control group (t test, P ¼ .043). In the absence of TAM treatment, mammary tumors in both control (n ¼ 50 tumors) and in utero EE2-exposed rats (n ¼ 46 tumors) grew and very few regressed spontaneously ( Figure 1A) . Thus, rats exposed to EE2 in utero were more likely than control rats to develop both de novo and acquired TAM-resistant mammary tumors.
Effect of Valproic Acid and Hydralazine on TAM Resistance in Rat Tumors
The effect of valproic acid and hydralazine on mammary tumor growth was then assessed in a group of control and EE2 rats: Neither group was responsive ( Figure 1A) . Consistent with the known safety profiles of these drugs, no toxicity was observed (Supplementary Table 3 , available online). We next assessed whether valproic acid and hydralazine improve response to TAM when added as a second-line treatment. In the in utero EE2 group, but not in controls, valproic acid and hydralazine reduced the development of de novo or acquired TAM-resistant tumors ( Figure  1B ). In the controls, the rate of new de novo TAM/valproic acid/ hydralazine-resistant tumors (appeared after treatment started) was 17.6% vs 25.4% with TAM only. In the EE2 rats, the rate of de novo resistant tumors fell to 15.0% vs 37.9% in the TAM-only group (Chi 2 test, P < .001) ( Figure 1B) . Furthermore, in the EE2 group, no tumors that responded to TAM-only treatment acquired resistance during TAM/valproic acid/hydralazine treatment ( Figure 1B) . The mammary tumor recurrence rate was not altered in the control group by adding valproic acid and hydralazine to TAM treatment ( Figure 1B) . Thus, valproic acid and 
Acquired TAM resistance
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hydralazine reduced the development of de novo and acquired TAM resistance only in the rats exposed to EE2 in utero. Mammary tumors in both the control and EE2 groups were ERa positive whether they were treated or not with TAM ( Figure  1C ). Mammary tumor histology also was similar in the two groups (Supplementary Table 4 , available online). Thus, changes in neither ER status nor tumor histotype explained anti-estrogen responsiveness.
Common Gene Regulation in In Utero EE2-Exposed Rat Tumors and Human Anti-Estrogen-Resistant LCC9 Breast Cancer Cells
Because mammary tumors in the EE2 group exhibited a higher rate of TAM resistance than tumors in the control rats, we studied whether the gene expression patterns of the EE2 tumors prior to any treatment broadly resemble those seen in TAM-resistant human LCC9 breast cancer cells (acquired resistance model, no treatment). The 48 DEGs are shown in Figure 2A , listed in Supplementary Tables 1, 5 , and 6, available online). Differential connections among transcription factors, which exist only in the LCC9/in utero EE2 grouping or only in the LCC1/ control grouping (identified using DDN analysis), are illustrated in Figure 2B . Six upregulated and six downregulated genes (nodes) with differential connections (edges) were identified in LCC9 vs LCC1 cells. Functions of these genes are provided in Table 1 . Nodes in LCC9 cells/mammary tumors from in utero EE2-exposed rats are connected to genes that result in anti-estrogen resistance, increased cancer cell proliferation and 
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Results of DDN analysis of microarray data survival, inhibition of apoptosis, and altered mitochondrial respiration and immune functions. To identify genes among the DEGs that may be causally linked to anti-estrogen resistance, we selected those that were predictive of survival among ERþ breast cancer patients treated with TAM (see "Methods"). These were the upregulated genes ETV4, HOXB3, MAST3, and WASF1 and the downregulated genes ARGHEF4, KLF4, LGALS3, and MICB. Expression of the eight genes was determined by performing quantitative polymerase chain reaction (qPCR) analysis of mRNA from an independent set of the LCC1 and LCC9 cells. Differential mRNA expression of all but the ARGHEF4 gene was confirmed.
Effect of Valproic Acid and Hydralazine on Gene Expression and Antiestrogen Resistance in LCC9 Cells
Among the differentially expressed genes, downregulation of KLF4, LGALS3, and MICB, and upregulation of ETV4, each were reversed in TAM-treated LCC9 cells exposed to valproic acid and hydralazine using doses comparable with those given to the rats and consistent with studies in other cancer models ( Figure  3A ) (20, 38) . Protein levels of ETV4, KLF4, LGALS3, and MICB (see below) were also determined using western blotting, and statistically significant changes between LCC1 and LCC9 cells were observed, consistent with the changes in mRNA expression (Supplementary Figure 2, available online) . Methylation status of ETV4, KLF4, LGALS3, and MICB is summarized in Figure 3B ; all three downregulated genes contained statistically significantly more methylated CpG islands in LCC9 cells compared with LCC1 cells. For the upregulated gene (ETV4), one CpG island in the TSS200-TSS1500 region was hypomethylated ( Figure 3B ), suggesting that reversal of ETV4 expression by valproic acid and hydralazine may be an indirect effect. These data indicate that alterations in the expression of genes related to the increased prevalence of TAM resistance seen with in utero estrogen treatment may be epigenetically induced.
TAM resistance in LCC9 cells was reversed by adding valproic acid or both valproic acid and hydralazine. Reversal of TAM resistance in LCC9 cells by valproic acid and hydralazine was dose dependent for TAM treatment (Figure 4) . The combination of valproic acid and hydralazine was additive. LGALS3 mRNA
LGALS3 versus GAPDH Reducing LGALS3 expression using RNAi reduced the response of LCC1 cells to TAM, compared with a control vector (two-way ANOVA, P ¼ .02) ( Figure 5A ). In contrast, knockdown of ETV4 in anti-estrogen-resistant LCC9 cells increased their response to TAM (two-way ANOVA, P ¼ .02) ( Figure 5B ). Silencing KLF4 or MICB had no effect on TAM responsiveness in LCC1 cells (data not shown). Recurrence-free survival in the three combined GEO datasets ( Figure 5C ) was statistically significantly shorter in ERþ breast cancers expressing the highest quartile of ETV4 and the lowest quartile of LGALS3 or KLF4. In a neoadjuvant study, tumors that responded to letrozole exhibited a statistically significant increase in KLF4 expression in the biopsy taken at 90 days of treatment ( Figure 5D ), but no changes were seen in the expression of ETV4, LGALS3, or MICB.
Discussion
Responses of ERþ mammary tumors to TAM in the DMBA model closely mimic those seen in ERþ breast cancer patients. For example, TAM reduces both the risk of breast cancer recurrence (39) and the development of primary tumors in high-risk women (40) by about 50%. In our study, a complete response to TAM was seen in 54% of the tumors in control rats. The rate of TAM resistance in our model also is broadly comparable with what is seen in breast cancer patients (41, 42) . Local recurrence over 15 weeks in rats, which corresponds to 10 human years (43), was 23%. In ERþ breast cancer patients treated with TAM, the 10-year overall recurrence rate is 22.7% (44) . Mammary tumors recurring with continued TAM treatment in rats express high levels of the endoplasmic reticulum chaperone GPR78 (45) and c-MYC (46) , which are mechanistically linked to TAM resistance (47, 48) . We determined whether the response to TAM is influenced by in utero exposure to EE2 and found that mammary tumors in these rats exhibited a statistically significantly higher rate of both de novo and acquired resistance to TAM than tumors in the control rats. Adding valproic acid and hydralazine to TAM as a second-line treatment reduced the development of de novo TAM resistance and recurrence in the rats exposed to EE2 in utero, but not in the controls. We chose to use valproic acid and hydralazine because these drugs improved the efficacy of radiotherapy and chemotherapy against advanced cervical and breast cancer in phases I, II, and III trials (49-52). Our findings 
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are consistent with observations in women showing a clinical benefit to adding the HDAC inhibitor vorinostat to TAM only for patients with endocrine therapy-resistant metastatic disease who exhibited elevated expression of HDAC2 (19) . We also searched for genes that are differentially expressed in the tumors of in utero EE2-exposed rats and their controls as they may be causally linked to the development of TAM resistance. We compared these genes with those differing in their expression values between anti-estrogen-sensitive (LCC1) and -resistant (LCC9) human breast cancer cells. The acquired anti-estrogen-resistant phenotype appears to involve increased DNA methylation (53) ; here, we found that a combined treatment with valproic acid and hydralazine reversed TAM resistance in LCC9 cells, consistent with earlier findings in other breast cancer models in vitro (16, 18) . We hypothesized that common differences in gene expression patterns in rat EE2 tumors and LCC9 human breast cancer cell lines prior to treatment would most likely be among the key drivers of anti-estrogen resistance resulting from in utero EE2 exposure. We explored interactions among the 48 differentially expressed genes using DDN analysis to extract potential network signaling features (54) . Specifically, DDN found differential connections among genes that exist only in the LCC9/in utero EE2 grouping or only in the LCC1/control grouping. Node-edge relationships identified genes in the LCC9 cells/in utero EE2 tumors related to increased anti-estrogen resistance (HSPB8 and RET) and altered tumor immune responses (CYP2RI, PTPN13, TRIM47, WASF1, and ZBTB14). In LCC1/control tumors, the nodes interacted with genes implicated in mitochondrial respiration, immune recognition and tumor suppressor activity, and inhibition of epithelial-mesenchymal transition (EMT). The comparison of rat mammary tumors and human breast cancer cells used here validates our approach of integrating insights from two model systems to identify new targets to prevent or reverse anti-estrogen resistance.
Of the differentially expressed genes, altered expression of KLF4, LGALS3, and MICB (each downregulated) and ETV4 (upregulated) was normalized in LCC9 cells by valproic acid and hydralazine. Notably, many CpG islands for KLF4, LGALS3, and MICB were more heavily methylated in the LCC9 than LCC1 cells. We found these differentially expressed genes to be predictive of poor survival in TAM-treated ERþ breast cancer patients. KLF4 inhibits EMT (55) and its expression is reduced in many cancers (56) , possibly through hypermethylation (57) .
LGALS3 is a key regulator of T-cell functions (58) , and its reduced expression, perhaps through methylation (59) , is linked to cancer progression and poor survival (60) . Importantly, we show that silencing LGALS3 by siRNA in LCC1 cells conferred TAM resistance. MICB encodes a glycosylated protein that binds to the NKG2D type II receptor and activates natural killer (NK) cells and cytotoxic T-cells (61) . Previously, treatment with valproic acid and hydralazine upregulated MICB and increased the cytotoxicity of NK cells against human breast cancer (38). The only upregulated gene, ETV4, can induce an EMT (62, 63) . We show that knocking down ETV4 in LCC9 cells restores TAM sensitivity, suggesting that ETV4 is mechanistically related to TAM resistance.
Our study has some limitations. While the animal model used here is generally reflective of ERþ human breast cancer, it may not capture all subtypes identified in women. Further, because endocrine resistance is a complex phenotype, we may not have identified all key genes/pathways altered by in utero estrogenic exposures that lead to endocrine resistance. Finally, it is not clear if our data is limited to TAM or is also reflective of developing resistance to other endocrine therapies because these therapies are not fully cross-resistant.
In summary, an elevated in utero estrogenic environment increased the risk of developing de novo and acquired TAM-resistant ERþ mammary tumors and increased the risk of local recurrence. Further, TAM resistance in in utero EE2 rat mammary tumors, but not in controls, was prevented by treatment with valproic acid and hydralazine. Comparison of gene expression patterns in the EE2 mammary tumors and LCC9 breast cancer cells indicated that the rat tumors are predisposed to fail antiestrogen therapy. Thus, resistance to TAM may be programmed by exposures to a highly estrogenic in utero environment that may arise naturally, because there is a substantial variation in estrogen levels in normal pregnancies (64) , or through exogenous exposure to estrogenic compounds from the environment (10, 11) .
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